Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Moderna Inc (NQ: MRNA )

43.06 -0.33 (-0.76%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna Inc

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
99 100 Next >
2 Artificial Intelligence (AI) in Healthcare Stocks to Buy and Hold for Great Long-Term Potential
These companies have gotten in on AI early and could emerge as winners. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Stocks Down 30% to Buy Right Now
These stocks have plenty of catalysts ahead. 
Via The Motley Fool
Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After Issuing Bird Flu Alert
Via Benzinga
1 New Green Flag for Moderna and Merck Stock
There's a new reason to believe that their joint projects are going well. 
Via The Motley Fool
$1000 Invested In Moderna 5 Years Ago Would Be Worth This Much Today
Via Benzinga
3 Pharma Stocks to Sell in April Before They Crash & Burn
Discover three pharma stocks to sell in April, facing challenges and signaling potential for significant downside. 
Via InvestorPlace
A Closer Look at Moderna's Options Market Dynamics
Via Benzinga
Moderna Inc. (NASDAQ: MRNA) Leading the Way in Tuesday Trading Based on Percentage Gain
Via Investor Brand Network
2 Stocks Down 30% and 27% to Buy and Hold
Look beyond these companies' challenges. 
Via The Motley Fool
If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names
Capitalize on the biotech sector's boom with these three top biotech stocks to buy, driven by aging demographics and advanced treatments. 
Via InvestorPlace
Declining COVID-19 Vaccine Sales Pinches Moderna, Pauses Kenya Vaccine Plant Plans
Moderna pauses plans for Kenya vaccine plant amid declining COVID-19 vaccine demand in Africa. Losses from unfulfilled orders prompt strategic shift. Efforts to finalize deal with Kenyan government... 
Via Benzinga
Exposures COVID-19
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE: 
Via Benzinga
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
These seven companies were the top 2020 stocks. After their glory years have faded, they are looking to turn their fortunes around. 
Via InvestorPlace
Why Is Moderna Stock Trading Higher On Tuesday?
Moderna stock jumps post AACR 2024 presentation of mRNA-4157 + Keytruda data in advanced HPV-negative head and neck carcinoma. Positive responses in the Phase 1 trial, with a 27.3% objective response... 
Via Benzinga
Stocks Fall Ahead Of Key Inflation Data, Gold Defends Record Highs; Bitcoin Stumbles Below $70,000: What's Driving Markets Tuesday?
Stocks edged lower during midday trading on Tuesday as traders maintained a cautious stance in anticipation of the highly awaited Consumer Price Index (CPI) report scheduled for Wednesday, which could... 
Via Benzinga
Topics Economy
Exposures Interest Rates
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday. Shares of BlackBerry Limited (NYSE: BB) rose sharply during Tuesday’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free 
Via Benzinga
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
These companies are close to launching new products that could supercharge revenue. 
Via The Motley Fool
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
These stocks, a bargain today, are players to hold on to for the long term. 
Via The Motley Fool
3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
The healthcare industry is one of the most potent yet also one of the most competitive. This has short sellers out for blood. 
Via InvestorPlace
Moderna's Vaccines Day 2024: A Glimpse into the Future of Infectious Disease Prevention
Moderna, Inc. (NASDAQ: MRNA) recently hosted its fourth annual Vaccines Day, offering a deep dive into the company's expanding infectious disease vaccines portfolio. 
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in April 2024
The most undervalued biotech stocks to buy in April are intriguing value options with mature biotech plays that boast impressive pipelines. 
Via InvestorPlace
Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge
Delaware Judge favors Arbutus and Genevant Sciences in their patent dispute with Moderna over COVID-19 vaccine technology. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead
Moderna stock falls 2.32% due to patent infringement suit. However, some investors see this as an opportunity to enter or average out. Golden Cross formation also offers hope for future growth. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Arbutus Stock Soars 20% As It Heads To Trial With Moderna In Covid Vaccine Patent Claim
Arbutus Biopharma soared more than 20% on Wednesday, April 3, after the company received permission to pursue a claim against Moderna in court. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
Via ACCESSWIRE
Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era
Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) did not only earn billions of dollars from their COVID-19 leading products but also rose to fame for saving the world from an unforeseen pandemic. 
Via Benzinga
Exposures COVID-19
Is Moderna Stock Going to $214? 1 Wall Street Analyst Thinks So.
Moderna, famous for its coronavirus vaccine, is only at the start of a trip skyward, a market professional believes. 
Via The Motley Fool
Exposures COVID-19
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.